Case Report: Pembrolizumab unmasks a capillary leak syndrome with chylothorax in early TNBC
Frontiers in Oncology · 22.05.2026 · 16
DOI: 10.3389/fonc.2026.1786343 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 22.05.2026. Verfasst von Naïla Benkalfate und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, Cayenne University Hospital, French Guiana, France. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pembrolizumab has become standard of care in early-stage triple-negative breast cancer (TNBC), but its expanding use may induce rare adverse events involving vascular and lymphatic endothelium. Capillary leak syndrome (CLS) remains an exceptionally rare toxicity of PD-1 blockade, scarcely reported in breast cancer, especially in the adjuvant setting. We report the case of a 40-year-old female with early-stage TNBC who presented with progressive dyspnea, diffuse subcutaneous edema and bilateral pleural and peritoneal effusions after two cycles of adjuvant pembrolizumab. Imaging confirmed polyserositis with interstitial pulmonary edema, and laboratory tests showed hypoalbuminemia without other abnormalities. Thoracentesis revealed milky pleural fluid containing chylomicrons, confirming chylothorax. Bronchoalveolar lavage, medical pleuroscopy, and pleural biopsies demonstrated a normal-appearing pleura without malignant or inflammatory infiltrates. Extensive workup ruled out infectious, neoplastic, cardiac, renal, and autoimmune causes, supporting pembrolizumab-induced vascular and lymphatic endothelial dysfunction. Corticosteroid therapy (1 mg/kg) led to rapid clinical and radiologic resolution. Pembrolizumab was permanently discontinued with no recurrence after corticosteroid tapering. This case highlights a rare but clinically significant immune-related adverse event (irAE) characterized by both vascular and lymphatic capillary leak under pembrolizumab. With PD-1 inhibitors increasingly used in curative TNBC, unexplained serous effusions and edema should prompt consideration of CLS and warrant comprehensive diagnostic evaluation to enable timely immunosuppression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pulmonology, Cayenne University Hospital, French Guiana, France.
- Department of Pathology, Cayenne University Hospital, French Guiana, France.
- Department of Oncology, Cayenne University Hospital, French Guiana, France.
- Department of Radiology, Cayenne University Hospital, French Guiana, France.
- Department of Internal Medicine, Cayenne University Hospital, French Guiana, France.
- Department of Pulmonology, Institut du Thorax, Nantes Université, Centre Hospitalo-Universitaire (CHU) Nantes, Nantes, France.
Zitieren
APA
Benkalfate, N., Hadjamara, G., Petorin, C., Zappa, M., Habonimana, A., Louis, D. P., Chene, A. L., Clarke, J. P., Liberge, R., Alsibai, K. D., Defrance, C., Pistilli, B., Boulet, B., Benguerfi, S., & Aissaoui, H. (2026). Case Report: Pembrolizumab unmasks a capillary leak syndrome with chylothorax in early TNBC. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1786343
Vancouver
Benkalfate N, Hadjamara G, Petorin C, Zappa M, Habonimana A, Louis DP, et al. Case Report: Pembrolizumab unmasks a capillary leak syndrome with chylothorax in early TNBC. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1786343
BibTeX
@article{Benkalfate2026,
author = {Benkalfate, Naïla and Hadjamara, Ghazi and Petorin, Caroline and Zappa, Magaly and Habonimana, Aimable and Louis, Dufens Pierre and Chene, Anne-Laure and Clarke, Jean-Patrick and Liberge, Renan and Alsibai, Kinane Drak and Defrance, Claire and Pistilli, Barbara and Boulet, Baptiste and Benguerfi, Soraya and Aissaoui, Houari},
title = {Case Report: Pembrolizumab unmasks a capillary leak syndrome with chylothorax in early TNBC},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1786343}
}
EUVIMED